Cargando…

Cisplatin alters nitric oxide synthase levels in human ovarian cancer cells: involvement in p53 regulation and cisplatin resistance

The present study determines if (1) basal protein levels of nitric oxide (NO) synthases (eNOS, iNOS, and nNOS) are different in cisplatin-sensitive (OV2008) and counterpart cisplatin-resistant (C13(*)) human ovarian cancer cells, (2) cisplatin alters NOS levels, (3) NO donor causes apoptosis and p53...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leung, E L, Fraser, M, Fiscus, R R, Tsang, B K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410127/ https://www.ncbi.nlm.nih.gov/pubmed/18506185 http://dx.doi.org/10.1038/sj.bjc.6604375

Ejemplares similares

Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
por: Yang, X, et al.
Publicado: (2008)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats
por: Uchino, H, et al.
Publicado: (2005)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations
por: Bodo, J, et al.
Publicado: (2006)

Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis
por: Duiker, E W, et al.
Publicado: (2011)

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012)

The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy
por: Yu, Y, et al.
Publicado: (2014)

Preclinical relevance of dosing time for the therapeutic index of gemcitabine–cisplatin
por: Li, X M, et al.
Publicado: (2005)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium
por: Blaheta, R A, et al.
Publicado: (2007)

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)

Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts
por: Chaudary, Naz, et al.
Publicado: (2017)

Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
por: Mendoza, J, et al.
Publicado: (2013)

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
por: Faivre, C, et al.
Publicado: (2017)

MicroRNA-204 increases sensitivity of neuroblastoma cells to cisplatin and is associated with a favourable clinical outcome
por: Ryan, J, et al.
Publicado: (2012)

Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer
por: Nitzsche, B, et al.
Publicado: (2012)

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
por: Fetoni, A R, et al.
Publicado: (2015)

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
por: Pisanu, M E, et al.
Publicado: (2014)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance
por: Englinger, B, et al.
Publicado: (2017)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein
por: Harris, M, et al.
Publicado: (2013)

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
por: Kashiwagi, Eiji, et al.
Publicado: (2018)

[(18)F]2-Fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil
por: Suttie, S A, et al.
Publicado: (2007)

Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas
por: Rahman, M T, et al.
Publicado: (2012)

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling
por: Wang, L-H, et al.
Publicado: (2014)

The combined activation of K(Ca)3.1 and inhibition of K(v)11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells
por: Pillozzi, Serena, et al.
Publicado: (2018)

The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers
por: Goto, T, et al.
Publicado: (2008)

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
por: Kim, J-S, et al.
Publicado: (2009)

Fatty acid synthase: a novel target for antiglioma therapy
por: Zhao, W, et al.
Publicado: (2006)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma
por: Bodet, L, et al.
Publicado: (2010)

Identification of thymidylate synthase as a potential therapeutic target for lung cancer
por: Takezawa, K, et al.
Publicado: (2010)

Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo
por: Clarke, P A, et al.
Publicado: (2004)

Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines
por: Chauhan, S S, et al.
Publicado: (2003)

The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas
por: Seguin, F, et al.
Publicado: (2012)

p53 mutation, deprivation and poor prognosis in primary breast cancer
por: Baker, L, et al.
Publicado: (2010)

Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer
por: Takezawa, K, et al.
Publicado: (2011)

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma
por: Bilim, V, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_d919096cfi9f52r1iau58no00b